NDB45_LYCMC
ID NDB45_LYCMC Reviewed; 74 AA.
AC B9UIY3;
DT 11-JAN-2011, integrated into UniProtKB/Swiss-Prot.
DT 24-MAR-2009, sequence version 1.
DT 25-MAY-2022, entry version 22.
DE RecName: Full=Mucroporin {ECO:0000303|PubMed:18779362};
DE AltName: Full=Antimicrobial peptide 36.21;
DE AltName: Full=Non-disulfide-bridged peptide 4.5 {ECO:0000303|PubMed:24184590};
DE Short=NDBP-4.5 {ECO:0000303|PubMed:24184590};
DE Flags: Precursor;
OS Lychas mucronatus (Chinese swimming scorpion).
OC Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Chelicerata; Arachnida;
OC Scorpiones; Buthida; Buthoidea; Buthidae; Lychas.
OX NCBI_TaxID=172552;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], SYNTHESIS OF MUCROPORIN, SYNTHESIS OF MUTANT
RP MUCROPORIN-M1, FUNCTION (MUCROPORIN), FUNCTION (MUCROPORIN-M1), AND
RP MUTAGENESIS OF GLY-25; PRO-28 AND 32-GLY-GLY-33.
RC STRAIN=Hainan; TISSUE=Venom gland;
RX PubMed=18779362; DOI=10.1128/aac.00542-08;
RA Dai C., Ma Y., Zhao Z., Zhao R., Wang Q., Wu Y.-L., Cao Z.-J., Li W.-X.;
RT "Mucroporin, the first cationic host defense peptide from the venom of
RT Lychas mucronatus.";
RL Antimicrob. Agents Chemother. 52:3967-3972(2008).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA].
RC STRAIN=Yunnan; TISSUE=Venom gland;
RX PubMed=20663230; DOI=10.1186/1471-2164-11-452;
RA Zhao R., Ma Y., He Y., Di Z., Wu Y.-L., Cao Z.-J., Li W.-X.;
RT "Comparative venom gland transcriptome analysis of the scorpion Lychas
RT mucronatus reveals intraspecific toxic gene diversity and new venomous
RT components.";
RL BMC Genomics 11:452-452(2010).
RN [3]
RP SYNTHESIS OF MUCROPORIN-M1, AND FUNCTION (MUCROPORIN-M1).
RX PubMed=21620914; DOI=10.1016/j.peptides.2011.05.015;
RA Li Q., Zhao Z., Zhou D., Chen Y., Hong W., Cao L., Yang J., Zhang Y.,
RA Shi W., Cao Z., Wu Y., Yan H., Li W.;
RT "Virucidal activity of a scorpion venom peptide variant mucroporin-M1
RT against measles, SARS-CoV and influenza H5N1 viruses.";
RL Peptides 32:1518-1525(2011).
RN [4]
RP SYNTHESIS OF MUCROPORIN-M1, AND FUNCTION (MUCROPORIN-M1).
RX PubMed=22791717; DOI=10.1074/jbc.m112.370312;
RA Zhao Z., Hong W., Zeng Z., Wu Y., Hu K., Tian X., Li W., Cao Z.;
RT "Mucroporin-M1 inhibits hepatitis B virus replication by activating the
RT mitogen-activated protein kinase (MAPK) pathway and down-regulating
RT HNF4alpha in vitro and in vivo.";
RL J. Biol. Chem. 287:30181-30190(2012).
RN [5]
RP SYNTHESIS OF MUCROPORIN, SYNTHESIS OF VARIANT MUCROPORIN-M1, FUNCTION
RP (MUCROPORIN), AND FUNCTION (MUCROPORIN-M1).
RX PubMed=22536342; DOI=10.1371/journal.pone.0034947;
RA Chen Y., Cao L., Zhong M., Zhang Y., Han C., Li Q., Yang J., Zhou D.,
RA Shi W., He B., Liu F., Yu J., Sun Y., Cao Y., Li Y., Li W., Guo D., Cao Z.,
RA Yan H.;
RT "Anti-HIV-1 activity of a new scorpion venom peptide derivative Kn2-7.";
RL PLoS ONE 7:E34947-E34947(2012).
RN [6]
RP NOMENCLATURE.
RX PubMed=24184590; DOI=10.1016/j.peptides.2013.10.021;
RA Almaaytah A., Albalas Q.;
RT "Scorpion venom peptides with no disulfide bridges: a review.";
RL Peptides 51:35-45(2014).
CC -!- FUNCTION: Mucroporin: cationic host defense peptide that have
CC antibacterial activity by breaking membranes. Is more effective on
CC Gram-positive than on Gram-negative bacteria. Minimum inhibitory
CC concentrations (MIC) are the following: MIC=>100 ug/ml against E.coli
CC AB94012, MIC=>100 ug/ml against P.aeruginosa AB93066, MIC=25 ug/ml
CC against B.thuringiensis AB92037, MIC=50 ug/ml against B.subtilis
CC AB91021, MIC=25 ug/ml against S.aureus AB94004, and MIC=25 ug/ml
CC against the methicillin-resistant coagulase-negative Staphylococcus.
CC Its synthetic analog mucroporin-M1 is more effective. Does not show
CC antiviral activity against any of measles, SARS-CoV, influenza H5N1,
CC hepatitis B and HIV-1 viruses.
CC -!- FUNCTION: Mutant mucroporin-M1: can inhibit Gram-positive bacteria at
CC low concentrations and antibiotic-resistant pathogens. Minimum
CC inhibitory concentrations (MIC) are the following: MIC=12.5 ug/ml
CC against E.coli AB94012, MIC=100 ug/ml against P.aeruginosa AB93066,
CC MIC=25 ug/ml against B.thuringiensis AB92037, MIC=25 ug/ml against
CC B.subtilis AB91021, MIC=5 ug/ml against S.aureus AB94004, and MIC=5
CC ug/ml against the methicillin-resistant coagulase-negative
CC Staphylococcus. Also shows antiviral activities against measles (EC(50)
CC of 7.15 ug/ml), SARS-CoV (EC(50) of 14.46 ug/ml), influenza H5N1
CC viruses (EC(50) of 2.10 mug/ml), HIV-1, and hepatitis B virus.
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250}. Target cell membrane.
CC Note=Forms a helical membrane channel in the prey. {ECO:0000250}.
CC -!- TISSUE SPECIFICITY: Expressed by the venom gland. {ECO:0000305}.
CC -!- SIMILARITY: Belongs to the non-disulfide-bridged peptide (NDBP)
CC superfamily. Short antimicrobial peptide (group 4) family.
CC {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; EU669864; ACF93401.1; -; mRNA.
DR EMBL; GT028857; -; NOT_ANNOTATED_CDS; mRNA.
DR AlphaFoldDB; B9UIY3; -.
DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR GO; GO:0042742; P:defense response to bacterium; IEA:UniProtKB-KW.
DR GO; GO:0050688; P:regulation of defense response to virus; IEA:UniProtKB-KW.
PE 1: Evidence at protein level;
KW Amidation; Antibiotic; Antimicrobial; Antiviral protein;
KW Cleavage on pair of basic residues; Membrane; Secreted; Signal;
KW Target cell membrane; Target membrane; Transmembrane.
FT SIGNAL 1..22
FT /evidence="ECO:0000250"
FT PEPTIDE 23..39
FT /note="Mucroporin"
FT /id="PRO_0000403858"
FT PROPEP 45..74
FT /evidence="ECO:0000250"
FT /id="PRO_0000403859"
FT MOD_RES 39
FT /note="Lysine amide"
FT /evidence="ECO:0000250"
FT MUTAGEN 25
FT /note="G->R: Increase in antibacterial activity; when
FT associated with K-28 and 32-G-G-33 (mutant mucroporin-M1)."
FT /evidence="ECO:0000269|PubMed:18779362"
FT MUTAGEN 28
FT /note="P->K: Increase in antibacterial activity; when
FT associated with R-25 and 32-G-G-33 (mutant mucroporin-M1)."
FT /evidence="ECO:0000269|PubMed:18779362"
FT MUTAGEN 32..33
FT /note="GG->KR: Increase in antibacterial activity; when
FT associated with R-25 and K-28 (mutant mucroporin-M1)."
FT /evidence="ECO:0000269|PubMed:18779362"
SQ SEQUENCE 74 AA; 8650 MW; 27C508C8AFE62F6D CRC64;
MKVKFLLAVF LIVLVVTDHC HALFGLIPSL IGGLVSAFKG RRKRQMEARF EPQNRNYRKR
ELDLEKLFAN MPDY
